Table 3 Adverse events in the normal-dose and the reduced-dose after propensity score matching in the TACE–apatinib group and TACE-Sorafenib group
Adverse events | TACE-Sorafenib group | TACE-Apatinib group | P | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Normal-dose | Reduced-dose | Normal-dose | Reduced-dose | |||||||||||||
All grade(n) | grade1/2(n) | grade3/4(n) | All grade(n) | grade1/2(n) | grade3/4(n) | All grade(n) | 1/2grade(n) | 3/4grade(n) | All grade(n) | 1/2grade(n) | 3/4grade(n) | P1 | P2 | P3 | P4 | |
Hand and foot syndrome | 61(52.59%) | 42(36.21%) | 19(16.38%) | 50(43.10%) | 42(36.21%) | 8(6.90%) | 65(56.03%) | 40(34.48%) | 25(19.84%) | 60(51.72%) | 48(41.38%) | 12(10.34%) | 0.598 | 0.189 | 0.064 | 0.023 |
Hypertension | 31(26.72%) | 20(17.24) | 11(9.48%) | 24(20.69%) | 19(16.38) | 5(4.31%) | 53(45.69%) | 38(32.76%) | 15(12.93%) | 40(34.48%) | 34(29.31%) | 6(5.17%) | 0.003 | 0.081 | 0.003 | 0.028 |
Proteinuria | 20(17.24%) | 12(10.34%) | 8(6.90%) | 15(12.93%) | 11(9.48%) | 4(3.45%) | 28(18.10%) | 18(15.52%) | 10(8.62%) | 16(13.79%) | 14(12.07%) | 2(1.72%) | 0.195 | 0.847 | 0.359 | 0.044 |
Alopecia | 6(5.17%) | 4(3.45%) | 2(1.72%) | 4(3.45%) | 3(2.59%) | 1(0.86%) | 5(4.31%) | 3(2.59%) | 2(1.72%) | 4(3.45%) | 3(2.59%) | 1(0.86%) | 0.757 | 1.000 | 0.778 | 0.635 |
Fatigue | 22(18.5%) | 19(16.38%) | 3(2.59%) | 18(15.52%) | 17(14.66%) | 1(0.86%) | 28(24.14%) | 23(19.83%) | 5(4.31%) | 19(16.38%) | 17(14.66%) | 2(1.72%) | 0.338 | 0.858 | 0.398 | 0.488 |
Decreased appetite | 24(20.69%) | 16(13.79%) | 8(6.90%) | 17(14.66%) | 15(12.93%) | 2(1.72%) | 27(23.28%) | 20(17.24) | 7(6.03%) | 13(11.21%) | 10(8.62%) | 3(2.59%) | 0.634 | 0.434 | 0.113 | 0.845 |
Diarrhea | 34(29.31%) | 30(25.86%) | 4(3.45%) | 21(18.10%) | 21(18.10%) | 0 | 17(14.66%) | 15(12.93%) | 2(1.72%) | 13(11.21%) | 12(10.34%) | 1(0.86%) | 0.002 | 0.137 | 0.111 | 0.713 |
Oral mucositis | 21(18.10%) | 19(16.38%) | 2(1.72%) | 15(12.93%) | 15(12.93%) | 0 | 36(31.03%) | 32(27.59%) | 4(3.45%) | 28(24.14%) | 25(21.55%) | 3(2.59%) | 0.022 | 0.028 | 0.218 | 0.959 |
hoarseness | 7(6.03%) | 6(5.17%) | 1(0.86%) | 4(3.45%) | 4(3.45%) | 0 | 10(8.62%) | 6(5.17%) | 4(3.45%) | 7(6.03%) | 6(5.17%) | 1(0.86%) | 0.449 | 0.354 | 0.428 | 0.252 |
Abdominal pain | 27(23.28%) | 24(20.69%) | 3(2.59%) | 21(18.10%) | 20(17.24%) | 1(0.86%) | 33(28.45%) | 28(24.14%) | 5(4.31%) | 27(23.28%) | 25(21.55%) | 2(1.72%) | 0.368 | 0.331 | 0.429 | 0.353 |
Hematotoxicity | 15(12.93%) | 13(11.21%) | 2(1.72%) | 10(8.62%) | 9(7.76%) | 1(0.86%) | 21(16.67%) | 16(13.79%) | 5(4.31%) | 15(12.93%) | 13(11.21%) | 2(1.72%) | 0.277 | 0.289 | 0.802 | 0.434 |
Rash | 24(20.68%) | 20(17.24%) | 4(3.45%) | 15(12.93%) | 13(11.21%) | 2(1.72%) | 26(22.41%) | 21(18.10%) | 5(4.31%) | 20(17.24%) | 17(14.66%) | 3(2.59%) | 0.749 | 0.359 | 0.779 | 0.707 |
Vomiting | 12(10.34%) | 10(8.62%) | 2(1.72%) | 8(6.90%) | 7(6.03%) | 1(0.86%) | 15(12.93%) | 12(10.34%) | 3(2.59%) | 12(10.34%) | 10(8.62%) | 2(1.72%) | 0.539 | 0.349 | 0.825 | 0.798 |
constipation | 4(3.45%) | 2(1.72%) | 2(1.72%) | 2(1.72%) | 2(1.72%) | 0 | 3(2.59%) | 2(1.72%) | 1(0.86%) | 1(0.86%) | 1(0.86%) | 0 | 0.701 | 0.561 | 0.221 | 0.386 |
headache | 11(9.48%) | 9(7.76%) | 2(1.72%) | 7(6.03%) | 7(6.03%) | 0 | 15(12.93%) | 12(10.34%) | 3(2.59%) | 10(8.62%) | 9(7.76%) | 1(0.86%) | 0.405 | 0.450 | 0.231 | 0.504 |
Liver dysfunction | 4(3.45%) | 3(2.59%) | 1(0.86%) | 2(1.72%) | 2(1.72%) | 0 | 6(5.17%) | 4(3.45%) | 2(1.72%) | 2(1.72%) | 2(1.72%) | 0 | 0.518 | 1.000 | 0.439 | 0.221 |
Gastrointestinal hemorrhage | 2(1.72%) | 2(1.72%) | 0 | 0 | 0 | 0 | 3(2.59%) | 2(1.72%) | 1(0.86%) | 1(0.86%) | 1(0.86%) | 0 | 0.651 | 0.316 | / | 0.505 |
number of cases | 63(54.31%) | 55(47.41%) | 87(75.00%) | 62(53.45%) | 0.001 | 0.358 | 0.293 | 0.001 | ||||||||